{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:56:29Z","timestamp":1789016189740,"version":"build-2803163510"},"reference-count":87,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The practicing pathologist is challenged by the ever-increasing diagnostic complexity of myeloid neoplasms. This guide is intended to provide a general roadmap from initial case detection, often triggered by complete blood count results with subsequent blood smear review, to final diagnosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The integration of hematologic, morphologic, immunophenotypic, and genetic features into routine practice is standard of care. The requirement for molecular genetic testing has increased along with the complexity of test types, the utility of different testing modalities in identifying key gene mutations, and the sensitivity and turnaround time for various assays.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Classification systems for myeloid neoplasms have evolved to achieve the goal of providing a pathology diagnosis that enhances patient care, outcome prediction, and treatment options for individual patients and is formulated, endorsed, and adopted by hematologists\/oncologists.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This guide provides diagnostic strategies for all myeloid neoplasm subtypes. Special considerations are provided for each category of testing and neoplasm category, along with classification information, genetic testing requirements, interpretation information, and case reporting recommendations based on the experience of 11 Bone Marrow Pathology Group members.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqad069","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T23:19:13Z","timestamp":1688167153000},"page":"365-393","source":"Crossref","is-referenced-by-count":6,"title":["Guide to the Diagnosis of Myeloid Neoplasms: A Bone Marrow Pathology Group Approach"],"prefix":"10.1093","volume":"160","author":[{"given":"Kathryn","family":"Foucar","sequence":"first","affiliation":[{"name":"Department of Pathology, University of New Mexico , Albuquerque, NM , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bagg","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Pennsylvania , Philadelphia, PA , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E","family":"Bueso-Ramos","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, University of Texas MD Anderson Cancer Center , Houston, TX , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"George","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Utah , Salt Lake City, UT , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P","family":"Hasserjian","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital , Boston, MA , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8623-4067","authenticated-orcid":false,"given":"Eric D","family":"Hsi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Wake Forest School of Medicine , Winston-Salem, NC , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Texas Tech University , El Paso, TX , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine , Hofstra\/Northwell, Greenvale, NY , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa A","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, University of Texas MD Anderson Cancer Center , Houston, TX , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga K","family":"Weinberg","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Southwestern Medical Center , Dallas, TX , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A","family":"Arber","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago , Chicago, IL , US"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"2023100314251777400_CIT0001","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ajh.26503","article-title":"Classificat+G3:G23ion of myeloid neoplasms\/acute leukemia: global perspectives and the international consensus classification approach","volume":"97","author":"Arber","year":"2022","journal-title":"Am J Hematol."},{"key":"2023100314251777400_CIT0002","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood."},{"key":"2023100314251777400_CIT0003","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/ijlh.13548","article-title":"Unsupervised flow cytometry analysis in hematological malignancies: a new paradigm","volume":"43","author":"B\u00e9n\u00e9","year":"2021","journal-title":"Int J Lab Hematol."},{"key":"2023100314251777400_CIT0004","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/cyto.b.21219","article-title":"Introduction to the diagnosis and classification of monocytic-lineage leukemias by flow cytometry","volume":"92","author":"Matarraz","year":"2017","journal-title":"Cytometry B Clin Cytom."},{"key":"2023100314251777400_CIT0005","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.5858\/arpa.2021-0124-OA","article-title":"Designing myeloid gene panels","volume":"146","author":"Zhao","year":"2022","journal-title":"Arch Pathol Lab Med."},{"key":"2023100314251777400_CIT0006","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood."},{"key":"2023100314251777400_CIT0007","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa2024534","article-title":"Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers","volume":"384","author":"Duncavage","year":"2021","journal-title":"N Engl J Med."},{"key":"2023100314251777400_CIT0008","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med."},{"key":"2023100314251777400_CIT0009","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood."},{"key":"2023100314251777400_CIT0010","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/ijlh.13771","article-title":"Comparison of flow cytometry with other modalities in the diagnosis of myelodysplastic syndrome","volume":"44","author":"Pembroke","year":"2022","journal-title":"Int J Lab Hematol."},{"key":"2023100314251777400_CIT0011","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00428-022-03417-1","article-title":"The International Consensus Classification of myelodysplastic syndromes and related entities","volume":"482","author":"Hasserjian","year":"2023","journal-title":"Virchows Arch."},{"key":"2023100314251777400_CIT0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00428-022-03430-4","article-title":"The International Consensus Classification of acute myeloid leukemia","volume":"482","author":"Weinberg","year":"2023","journal-title":"Virchows Arch."},{"key":"2023100314251777400_CIT0013","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/ajcp\/aqac016","article-title":"How I diagnose primary myelofibrosis","volume":"157","author":"Prakash","year":"2022","journal-title":"Am J Clin Pathol."},{"key":"2023100314251777400_CIT0014","doi-asserted-by":"crossref","DOI":"10.1159\/isbn.978-3-318-06867-2","volume-title":"ISCN 2020: An International System for Human Cytogenomic Nomenclature (2020).","author":"McGowan-Jordan","year":"2020"},{"key":"2023100314251777400_CIT0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1309\/AJCPI9C8UILYQTNS","article-title":"Acute myeloid leukemia with recurrent cytogenetic abnormalities","volume":"144","author":"Foucar","year":"2015","journal-title":"Am J Clin Pathol."},{"key":"2023100314251777400_CIT0016","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00428-022-03447-9","article-title":"The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia","volume":"482","author":"Rudelius","year":"2023","journal-title":"Virchows Arch."},{"key":"2023100314251777400_CIT0017","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1182\/blood-2018-06-860882","article-title":"How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes [published correction appears in Blood. 2018;132(22):2419]","volume":"132","author":"Steensma","year":"2018","journal-title":"Blood."},{"key":"2023100314251777400_CIT0018","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00428-022-03480-8","article-title":"International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms","volume":"482","author":"Gianelli","year":"2023","journal-title":"Virchows Arch."},{"key":"2023100314251777400_CIT0019","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ajh.26455","article-title":"Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Patnaik","year":"2022","journal-title":"Am J Hematol."},{"key":"2023100314251777400_CIT0020","volume-title":"Bone Marrow Pathology","author":"Foucar","year":"2020"},{"key":"2023100314251777400_CIT0021","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41375-021-01498-6","article-title":"\u201cBlasts\u201d in myeloid neoplasms\u2014how do we define blasts and how do we incorporate them into diagnostic schema moving forward","volume":"36","author":"Chen","year":"2022","journal-title":"Leukemia."},{"key":"2023100314251777400_CIT0022","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/PAI.0000000000000139","article-title":"\u03b1-Hemoglobin-stabilizing protein: an effective marker for erythroid precursors in bone marrow biopsy specimens","volume":"24","author":"Yu","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol."},{"key":"2023100314251777400_CIT0023","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1097\/PAS.0b013e31825fa501","article-title":"\u03b1-Hemoglobin-stabilizing protein is a sensitive and specific marker of erythroid precursors","volume":"36","author":"Raess","year":"2012","journal-title":"Am J Surg Pathol."},{"key":"2023100314251777400_CIT0024","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.26751","article-title":"The International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: myeloproliferative neoplasms [published correction appears in Am J Hematol. January 4, 2023]","volume":"98","author":"Thiele","year":"2023","journal-title":"Am J Hematol."},{"key":"2023100314251777400_CIT0025","article-title":"The International Consensus Classification of acute leukemias of ambiguous lineage [published online March 6, 2023]","author":"Weinberg","journal-title":"Blood."},{"key":"2023100314251777400_CIT0026","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood."},{"key":"2023100314251777400_CIT0027","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00428-022-03423-3","article-title":"The International Consensus Classification of mastocytosis and related entities","volume":"482","author":"Leguit","year":"2023","journal-title":"Virchows Arch."},{"key":"2023100314251777400_CIT0028","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/ijlh.13212","article-title":"Concordance among hematopathologists in classifying blasts plus promonocytes: a Bone Marrow Pathology Group study","volume":"42","author":"Foucar","year":"2020","journal-title":"Int J Lab Hematol."},{"key":"2023100314251777400_CIT0029","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00428-022-03465-7","article-title":"Advances in myelodysplastic\/myeloproliferative neoplasms","volume":"482","author":"Prakash","year":"2023","journal-title":"Virchows Arch."},{"key":"2023100314251777400_CIT0030","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/ijlh.13607","article-title":"How I investigate dysgranulopoiesis","volume":"43","author":"Shekhar","year":"2021","journal-title":"Int J Lab Hematol."},{"key":"2023100314251777400_CIT0031","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1097\/PAS.0000000000001732","article-title":"Genetic and clinical studies of patients with increased multinucleated megakaryocytes in bone marrow as an isolated finding: a diagnostic pitfall for myelodysplastic syndrome","volume":"45","author":"Zheng","year":"2021","journal-title":"Am J Surg Pathol."},{"key":"2023100314251777400_CIT0032","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ijlh.13536","article-title":"Cytomorphology of normal, reactive, dysmorphic, and dysplastic megakaryocytes in bone marrow aspirates","volume":"43","author":"Zini","year":"2021","journal-title":"Int J Lab Hematol."},{"key":"2023100314251777400_CIT0033","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2014.161","article-title":"Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes","volume":"29","author":"Della Porta","year":"2015","journal-title":"Leukemia."},{"key":"2023100314251777400_CIT0034","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/ajcp\/aqw144","article-title":"Increased multinucleated megakaryocytes as an isolated finding in bone marrow: a rare finding and its clinical significance","volume":"146","author":"Jawad","year":"2016","journal-title":"Am J Clin Pathol."},{"key":"2023100314251777400_CIT0035","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood."},{"key":"2023100314251777400_CIT0036","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","article-title":"Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia","volume":"125","author":"Selimoglu-Buet","year":"2015","journal-title":"Blood."},{"key":"2023100314251777400_CIT0037","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3324\/haematol.2020.247569","article-title":"Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm","volume":"106","author":"Wang","year":"2021","journal-title":"Haematologica."},{"key":"2023100314251777400_CIT0038","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood."},{"key":"2023100314251777400_CIT0039","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cyto.b.22044","article-title":"Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: a report of the European LeukemiaNet International MDS-Flow Cytometry Working Group","volume":"104","author":"van de Loosdrecht","year":"2023","journal-title":"Cytometry B Clin Cytom."},{"key":"2023100314251777400_CIT0040","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1309\/4W2G3NDXUPG5J33N","article-title":"Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes","volume":"129","author":"Maftoun-Banankhah","year":"2008","journal-title":"Am J Clin Pathol."},{"key":"2023100314251777400_CIT0041","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cyto.b.21830","article-title":"Low-grade myelodysplastic syndromes with preserved CD34+ B-cell precursors (CD34+ hematogones)","volume":"98","author":"Chen","year":"2020","journal-title":"Cytometry B Clin Cytom."},{"key":"2023100314251777400_CIT0042","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1309\/UXCDG9PWN7G89Y54","article-title":"CD79a is heterogeneously expressed in neoplastic and normal myeloid precursors and megakaryocytes in an antibody clone-dependent manner","volume":"128","author":"Bhargava","year":"2007","journal-title":"Am J Clin Pathol."},{"key":"2023100314251777400_CIT0043","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1309\/HDUE-DN2E-B72E-JK99","article-title":"Myeloperoxidase immunoreactivity in adult acute lymphoblastic leukemia","volume":"116","author":"Arber","year":"2001","journal-title":"Am J Clin Pathol."},{"key":"2023100314251777400_CIT0044","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/ajcp\/aqx021","article-title":"Clinical significance of isolated myeloperoxidase expression in pediatric B-lymphoblastic leukemia [published correction appears in Am J Clin Pathol. 2017;148(3):280]","volume":"147","author":"Oberley","year":"2017","journal-title":"Am J Clin Pathol."},{"key":"2023100314251777400_CIT0045","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.hoc.2019.11.006","article-title":"The clinical management of clonal hematopoiesis: creation of a clonal hematopoiesis clinic","volume":"34","author":"Bolton","year":"2020","journal-title":"Hematol Oncol Clin North Am."},{"key":"2023100314251777400_CIT0046","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ijlh.13802","article-title":"The value of next-generation sequencing in routine diagnostics and management of patients with cytopenia","volume":"44","author":"Breinholt","year":"2022","journal-title":"Int J Lab Hematol."},{"key":"2023100314251777400_CIT0047","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1182\/bloodadvances.2017007922","article-title":"Copy number alterations detected as clonal hematopoiesis of indeterminate potential","volume":"1","author":"Takahashi","year":"2017","journal-title":"Blood Adv."},{"key":"2023100314251777400_CIT0048","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","article-title":"Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1","volume":"5","author":"Obiorah","year":"2021","journal-title":"Blood Adv."},{"key":"2023100314251777400_CIT0049","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.seminhematol.2021.10.004","article-title":"Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones","volume":"58","author":"Kusne","year":"2021","journal-title":"Semin Hematol."},{"key":"2023100314251777400_CIT0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood.2019000942","article-title":"Genetics of progression from MDS to secondary leukemia","volume":"136","author":"Menssen","year":"2020","journal-title":"Blood."},{"key":"2023100314251777400_CIT0051","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/ijlh.13840","article-title":"Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia-related changes: a single institution experience","volume":"44","author":"Gao","year":"2022","journal-title":"Int J Lab Hematol."},{"key":"2023100314251777400_CIT0052","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.26772","article-title":"International Consensus Classification for myeloid neoplasms at-a-glance","volume":"98","author":"Orazi","year":"2023","journal-title":"Am J Hematol."},{"key":"2023100314251777400_CIT0053","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/modpathol.2014.160","article-title":"Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations","volume":"28","author":"Ohgami","year":"2015","journal-title":"Mod Pathol."},{"key":"2023100314251777400_CIT0054","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia."},{"key":"2023100314251777400_CIT0055","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes [published correction appears in Nat Med. 2021;27(3):562] [published correction appears in Nat Med. 2021;27(5):927]","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med."},{"key":"2023100314251777400_CIT0056","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv."},{"key":"2023100314251777400_CIT0057","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/ijlh.13864","article-title":"Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype","volume":"44","author":"Xu","year":"2022","journal-title":"Int J Lab Hematol."},{"key":"2023100314251777400_CIT0058","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood."},{"key":"2023100314251777400_CIT0059","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N Engl J Med."},{"key":"2023100314251777400_CIT0060","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/hematology.2022000349","article-title":"Risk stratifying MDS in the time of precision medicine","volume":"2022","author":"Cazzola","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"2023100314251777400_CIT0061","article-title":"Impact of the International Consensus Classification of myelodysplastic syndromes [published online December 28, 2022]","author":"Zhang","journal-title":"Br J Haematol."},{"key":"2023100314251777400_CIT0062","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ajh.26799","article-title":"Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome\/acute myeloid leukemia based on the 2022 International Consensus Classification","volume":"98","author":"Lee","year":"2023","journal-title":"Am J Hematol."},{"key":"2023100314251777400_CIT0063","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41379-021-00961-0","article-title":"Myelodysplastic\/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group [published correction appears in Mod Pathol. December 13, 2021]","volume":"35","author":"Kanagal-Shamanna","year":"2022","journal-title":"Mod Pathol."},{"key":"2023100314251777400_CIT0064","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.2019004229","article-title":"Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms","volume":"136","author":"Palomo","year":"2020","journal-title":"Blood."},{"key":"2023100314251777400_CIT0065","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1182\/bloodadvances.2022007359","article-title":"Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum","volume":"6","author":"Calvo","year":"2022","journal-title":"Blood Adv."},{"key":"2023100314251777400_CIT0066","doi-asserted-by":"crossref","first-page":"101134","DOI":"10.1016\/j.beha.2019.101134","article-title":"Incorporating flow cytometry and next-generation sequencing in the diagnosis of CMML. Are we ready for prime","volume":"33","author":"Solary","year":"2020","journal-title":"Best Pract Res Clin Haematol."},{"key":"2023100314251777400_CIT0067","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.hoc.2020.12.001","article-title":"Overview of myeloproliferative neoplasms: history, pathogenesis, diagnostic criteria, and complications","volume":"35","author":"Tremblay","year":"2021","journal-title":"Hematol Oncol Clin North Am."},{"key":"2023100314251777400_CIT0068","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol."},{"key":"2023100314251777400_CIT0069","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3324\/haematol.2017.165340","article-title":"Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome","volume":"102","author":"Wang","year":"2017","journal-title":"Haematologica."},{"key":"2023100314251777400_CIT0070","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ajh.26481","article-title":"Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management","volume":"97","author":"Szuber","year":"2022","journal-title":"Am J Hematol."},{"key":"2023100314251777400_CIT0071","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.2019000611","article-title":"Genomic landscape of neutrophilic leukemias of ambiguous diagnosis","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood."},{"key":"2023100314251777400_CIT0072","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/ajh.24837","article-title":"European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia","volume":"92","author":"Kvasnicka","year":"2017","journal-title":"Am J Hematol."},{"key":"2023100314251777400_CIT0073","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1002\/cncr.31663","article-title":"Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: assessment of potential value","volume":"124","author":"Hidalgo-L\u03ccpez","year":"2018","journal-title":"Cancer."},{"key":"2023100314251777400_CIT0074","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00428-022-03402-8","article-title":"Updates on eosinophilic disorders","volume":"482","author":"Tzankov","year":"2023","journal-title":"Virchows Arch."},{"key":"2023100314251777400_CIT0075","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ajh.25018","article-title":"A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1\/2 mutations and improved outcome","volume":"93","author":"Mason","year":"2018","journal-title":"Am J Hematol."},{"key":"2023100314251777400_CIT0076","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41408-022-00746-x","article-title":"Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases","volume":"12","author":"Reichard","year":"2022","journal-title":"Blood Cancer J."},{"key":"2023100314251777400_CIT0077","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1309\/B4NVER1AJJ84CTUU","article-title":"Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis","volume":"127","author":"Soupir","year":"2007","journal-title":"Am J Clin Pathol."},{"key":"2023100314251777400_CIT0078","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/ajh.25769","article-title":"Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy","volume":"95","author":"Montalban-Bravo","year":"2020","journal-title":"Am J Hematol."},{"key":"2023100314251777400_CIT0079","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/bloodadvances.2020002474","article-title":"Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients","volume":"4","author":"Laribi","year":"2020","journal-title":"Blood Adv."},{"key":"2023100314251777400_CIT0080","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal","volume":"5","author":"Valent","year":"2021","journal-title":"Hemasphere"},{"key":"2023100314251777400_CIT0081","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2019000932","article-title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","volume":"135","author":"Reiter","year":"2020","journal-title":"Blood."},{"key":"2023100314251777400_CIT0082","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.anai.2021.08.009","article-title":"Clinical relevance of inherited genetic differences in human tryptases: hereditary alpha-tryptasemia and beyond","volume":"127","author":"Glover","year":"2021","journal-title":"Ann Allergy Asthma Immunol."},{"key":"2023100314251777400_CIT0083","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.2022017865","article-title":"North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need","volume":"141","author":"Pemmaraju","year":"2023","journal-title":"Blood."},{"key":"2023100314251777400_CIT0084","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/ajcp\/aqaa208","article-title":"Myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2","volume":"155","author":"Pozdnyakova","year":"2021","journal-title":"Am J Clin Pathol."},{"key":"2023100314251777400_CIT0085","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41379-018-0165-9","article-title":"Hematopoietic neoplasms with 9p24\/JAK2 rearrangement: a multicenter study","volume":"32","author":"Tang","year":"2019","journal-title":"Mod Pathol."},{"key":"2023100314251777400_CIT0086","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/s41379-021-00817-7","article-title":"Myeloid\/lymphoid neoplasms with FLT3 rearrangement","volume":"34","author":"Tang","year":"2021","journal-title":"Mod Pathol."},{"key":"2023100314251777400_CIT0087","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/160\/4\/365\/51838875\/aqad069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/160\/4\/365\/51838875\/aqad069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T17:17:45Z","timestamp":1696353465000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/160\/4\/365\/7216407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":87,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,6,30]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqad069","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,6,30]]}}}